Ask AI
Managing AEs in Relapsed ES-SCLC

CE / CME

Mitigating and Managing AEs Associated With Newer Agents for Relapsed ES-SCLC

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: December 02, 2025

Expiration: June 01, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Ticiana Leal, MD, explores strategies for mitigating and managing AEs associated with newer therapies for relapsed ES-SCLC, integrating real-world case examples, clinical trial data, and practical approaches to monitoring and intervention. This module is part of a larger program on ES-SCLC and additional modules can be found here.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 62-year-old woman with relapsed extensive-stage (ES) small-cell lung cancer (SCLC) and Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 is receiving cycle 1 Day 1 of tarlatamab (1 mg IV) in the outpatient setting and 8 hours post infusion, she develops a temperature of 38.7°C with mild tachycardia (heart rate 104 beats/min). In addition to ruling out infection, what is the most appropriate next step in her management?

A 63-year-old patient with relapsed ES-SCLC is starting treatment with single-agent lurbinectedin. What would you tell him about expected adverse events (AEs)?

How many patients with SCLC do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: